Provide feedbackProvide feedback

Home :: Endocrinology

NHANES data show increased prevalence of vision loss, impairment among adults with diabetes

Wednesday, November 19 2008 | Comments
Evidence Grade 9 What's This?

Data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) confirm that vision loss is significantly more common among adults with diabetes than it is among adults without diabetes. Researchers with the Centers for Disease Control and Prevention used NHANES data to determine the prevalence and correlates of vision impairment among U.S adults with and without diabetes. Based on data from 13,004 survey participants, the research team estimated the prevalence of...

Data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) confirm that vision loss is significantly more common among adults with diabetes than it is among adults without diabetes.

Researchers with the Centers for Disease Control and Prevention used NHANES data to determine the prevalence and correlates of vision impairment among U.S adults with and without diabetes. Based on data from 13,004 survey participants, the research team estimated the prevalence of presenting (correctable or uncorrectable), correctable, and uncorrectable vision impairment among Americans aged 20 years or older.

The findings suggested that people with diabetes have a 60% higher prevalence of correctable vision impairment and a 170% higher prevalence of uncorrectable vision impairment relative to those without diabetes.

Approximately 11% of Americans with diabetes had some form of vision impairment (9.7% moderate and 1.4% severe), including 7.2% with correctable impairment and 3.8% with uncorrectable impairment (2.9% moderate and 1.0% severe). Among those without diabetes, the prevalence of vision impairment was 5.9% (5.1% moderate and 0.9% severe), including 4.5% with correctable impairment and 1.4% with uncorrectable impairment (1.2% moderate and 0.3% severe).

The risk of uncorrectable vision impairment remained significantly associated with diabetes, even after controlling for age, sex, marital status, race/ethnicity, educational level, income, health insurance, high blood pressure, smoking, and body mass index (OR, 1.49; 95% CI, 1.01-2.20).

Although diabetes was also associated with correctable vision impairment in an age-adjusted analysis, this association was not significant in the fully adjusted model.

Other factors that were independently associated with vision loss included older age, nonwhite race/ethnicity, lower income, and lack of health insurance.

NHANES does not include the institutionalized nursing home population, which may have led to an underestimate of vision impairment prevalence generally, the researchers noted.

They added that several other factors might have contributed to an underestimation of vision impairment, including the fact that participants who were completely blind, unable to see in both eyes, or had a severe infection in one or both eyes were excluded from vision examination.

"Our findings underscore the importance of the use of an annual comprehensive eye examination for people with diabetes," the authors concluded, adding that an annual comprehensive eye examination would help clinicians identify risk factors for uncorrectable VI, detect diabetic retinopathy and other ocular conditions at their early stages, and ensure appropriate and continuous eye care, thus prevent or delay permanent vision loss. (Zhang X, et al. Arch Ophthalmol 2008;126:1421-1427.)

Latest News

Greater fish consumption associated with reduced risk of macroalbuminuria in patients with diabetes, data find Verusmed

Wednesday, November 19 2008 | Comments
Evidence Grade 11 What's This?
Fish consumption may help lower the risk of macroalbuminuria in individuals with diabetes, suggests a cross-sectional study.

Researchers hypothesized that fish consumption would be associated with decreased albuminuria in people with and without diabetes. To test this hypothesis, they examined data from a subgroup of the European Prospective Investigation of Cancer, a population-based cohort study designed to assess the relationship between diet and cancer.

...

Metformin offers moderate protection against cardiovascular outcomes, meta-analysis suggests Verusmed

Wednesday, November 19 2008 | Comments
Evidence Grade 2 What's This?
Patients with type 2 diabetes who take metformin hydrochloride may receive moderate protection against adverse cardiovascular outcomes, while rosiglitazone maleate may increase the risk of such events, suggests a new meta-analysis. But researchers caution that large, long-term studies are required to draw firm conclusions about the major clinical benefits and risks related to oral diabetes agents.

The study, conducted by the Johns Hopkins...


Change in percent atheroma volume similar following treatment with rosiglitazone, glipizide in patients with type 2 diabetes, APPROACH data show Verusmed

Sunday, November 16 2008 | Comments
Evidence Grade 7 What's This?
By Selma Kaszczuk

The effect of the insulin sensitizer rosiglitazone versus that of the insulin secretagogue glipizide on intravascular ultrasound (IVUS) measures of atherosclerosis in native coronary arteries among patients with type 2 diabetes do not appear to significantly differ, according to Dr. Richard Nesto, chairman of cardiovascular medicine at Lahey Clinic in Burlington, MA, who...

Drug-eluting stents do not increase risk of death, MI relative to bare-metal stents in patients with diabetes during long-term follow-up, analysis reveals Verusmed

Thursday, November 13 2008 | Comments
Evidence Grade 7 What's This?
By Selma Kaszczuk

Patients with diabetes who are treated with drug-eluting stents (DES) experience no increased risk of death or myocardial infarction (MI) during long-term follow-up as compared with patients who receive bare-metal stents (BMS), new findings suggest.

Approximately one-third of individuals presenting for coronary stenting...